Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894559 | 1.00 | HPGD (0.54) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL389962 | 1.00 | HPGD (0.54) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL442932 | 0.92 | MEN1 (0.56) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL968401 | 0.92 | MEN1 (0.56) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL1249710 | 0.92 | MEN1 (0.56) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL407899 | 0.91 | HPGD (0.56) | HPGDRECQLKMT2AALDH1A1MAPT | |
| SCHEMBL3615534 | 0.91 | HPGD (0.53) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL278133 | 0.88 | NR1H2 (0.45) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL2153593 | 0.87 | HPGD (0.57) | HPGDUSP30RECQLKMT2AALDH1A1 | |
| SCHEMBL14348065 | 0.87 | HPGD (0.57) | HPGDUSP30RECQLKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | ACERTA PHARMA B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| EP-4680609-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250360112-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | ACERTA PHARMA BV (NL) | 2025-11-27 | — | — | US | disclosed |
| US-20240335431-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | ACERTA PHARMA B.V. (NL) | 2024-10-10 | — | — | US | disclosed |
| WO-2024192424-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2023235380-A1 | MACROLIDES FOR TREATING GENETIC DISEASES | ZIKANI THERAPEUTICS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4041229-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2010117979-A2 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010011811-A2 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| EP-1685101-A1 | N-ACYLATED-3-(BENZOYL)-PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047250-A1 | N-ACYLATED-3- (BENZOYL) - PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | HSD11B1, HSD3B1, HSD17B1 | HPGD 39/4885USP30 1588/4885RECQL 3199/4885 |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | SLC6A2, SLC6A4, TPH1 | HPGD 679/4885USP30 3358/4885RECQL 831/4885 |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL12, RPL13A | HPGD 2354/4885USP30 2664/4885RECQL 3834/4885 |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | MEN1, PKD1, PKD2 | HPGD 2427/4885USP30 4846/4885RECQL 2122/4885 |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | HPGD 2590/4885USP30 4056/4885RECQL 2939/4885 |
| US-20240335431-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | MEN1, PKD1, ADCYAP1R1 | HPGD 670/4885USP30 4736/4885RECQL 29/4885 |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | HPGD 1213/4885USP30 4480/4885RECQL 516/4885 |
| US-20250360112-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | MEN1, PKD1, ADCYAP1R1 | HPGD 670/4885USP30 4736/4885RECQL 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.